23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...
CEO Anne Wojcicki last spring proposed buying out the company and taking it private. Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said ...
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, ...
Zacks.com on MSN11d
NGVT to Evaluate Strategic Alternatives for Industrial SpecialtiesIngevity Corporation NGVT recently announced plans to explore strategic alternatives for its Performance Chemicals Industrial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback